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Abstract Fatigue accounts for an important part of the
burden experienced by patients with neuromuscular disor-
ders. Substantial high prevalence rates of fatigue are
reported in a wide range of neuromuscular disorders, such
as Guillain–Barre´ syndrome and Pompe disease. Fatigue
can be subdivided into experienced fatigue and physio-
logical fatigue. Physiological fatigue in turn can be of
central or peripheral origin. Peripheral fatigue is an
important contributor to fatigue in neuromuscular disor-
ders, but in reaction to neuromuscular disease fatigue of
central origin can be an important protective mechanism to
restrict further damage. In most cases, severity of fatigue
seems to be related with disease severity, possibly with the
exception of fatigue occurring in a monophasic disorder
like Guillain–Barre´ syndrome. Treatment of fatigue in
neuromuscular disease starts with symptomatic treatment
of the underlying disease. When symptoms of fatigue
persist, non-pharmacological interventions, such as exer-
cise and cognitive behavioral therapy, can be initiated.
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Introduction
Everybody experiences periods of fatigue, but these usually
can be mended by taking a rest or enjoying a good night’s
sleep. In a wide range of diseases, however, fatigue is a well-
known chronic symptom. In patients without demonstrable
somatic disease chronic fatigue may occur and may lead to
the diagnosis of chronic fatigue syndrome [31]. Severe
fatigue as a chronic symptom and its impact on daily living
are starting to receive more and more attention as patient-
reported outcome measures in clinical trials in patients with
somatic disease. Several studies have demonstrated that
fatigue is a disabling symptom in chronic diseases such as
cancer, but also in a variety of neurological disorders and
conditions (Table 1) [14]. Severe fatigue can also occur as a
side effect of drugs like beta-blockers, proton-pump inhib-
itors, anxiolytic drugs and antipsychotics [2].
The first studies on fatigue in neurological diseases
focused on diseases of the central nervous system (CNS),
such as cerebrovascular disease, multiple sclerosis and
Parkinson’s disease [29, 30, 44, 54, 88, 106]. Nowadays, it
is recognized that fatigue is also an important and fre-
quently occurring symptom in disorders of the peripheral
nervous system (PNS) with a high impact on physical
abilities and perceived health status in these patients [104].
This review focuses on fatigue in neuromuscular disor-
ders, with emphasis on fatigue in Guillain–Barre´ syndrome
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(GBS), an immune-mediated polyradiculoneuropathy, and
Pompe disease, a metabolic muscle disorder. Various
aspects of fatigue will be discussed, including differences
between experienced and physiological fatigue and differ-
ent methods available for assessment of fatigue. GBS and
Pompe disease are taken as examples to discuss possible
pathological mechanisms of fatigue, treatment strategies
and options for future research.
Different types of fatigue and their definitions
Fatigue covers a broad spectrum of symptoms and com-
plaints, and has no uniform definition. In clinical research,
commonly used definitions of fatigue are an overwhelming
and persistent feeling of tiredness and diminished ability to
sustain voluntary mental and physical activities. In addi-
tion, weakness, lethargy and lack of energy that interfere
with daily activities are used as definitions [9, 13, 22, 23,
29, 51, 53, 57, 107]. In basic neurosciences, it is defined as
a time-related force decline [32, 102]. Considering the
different aspects of fatigue it is best regarded as a multi-
dimensional concept in which the level of experienced
fatigue and the ability to perform activities are influenced
by the type of disease, the health status of the patient and
several aspects of patient functioning. A distinction is made
between experienced fatigue and physiological fatigue,
which can both be influenced by psycho-sociological fac-
tors [101]. The multidimensional concept of fatigue is
depicted in Fig. 1. In this figure fatigue is integrated in the
World Health Organization’s International Classification of
Functioning, Disability and Health (WHO-ICF). The
WHO-ICF represents the effect of disease on body function
and structure and the level of activities and participation of
the patient [1].
Physiology of fatigue
With electrophysiological testing, fatigue can be measured
as a loss of voluntary force-producing capacity of the
muscles during exercise [8, 72]. To understand this reduced
capacity of the muscle it is important to know how fatigue
arises. The central governor model clarifies in a logical
way how fatigue arises during mental or physical effort and
how fatigue is essential for protecting the body against
damage due to excessive exercise [69]. During performed
effort the CNS is continuously informed about the level of
perceived exertion by feedback from muscles, joints, body
temperature, the cardiorespiratory system and cognitive
domains (afferent pathways). This feedback is processed at
the primary somatic sensory cortex, subsequently sensory
motor integration takes place and the activation by the
primary motor cortex of the brainstem motor nuclei and
anterior horn cells in the spinal cord (efferent pathway) is
adjusted if needed to maintain body homeostasis. This
continuous feed forward and feedback control mechanisms
regulate the work rate and determines when rest is needed
[14, 69].
With this model it is not fully explained how severe
fatigue can be present in chronic disease or how fatigue can
be present in a resting situation. In patients with severe
fatigue the sense of normal fatigue is amplified due to
pathological changes in the motor system, disruption of
feedback to the primary somatic sensory cortex and/or
change in patients’ motivation [14, 69]. In a resting situa-
tion an estimation is made whether the body can cope with
an increase in effort. Up-regulation of metabolism occurs
during exercise; however, in case of disease, the capacity to
increase the metabolic rate is limited. This is perceived at
the level of the CNS as fatigue and the patient will avoid
excessive effort and requires rest.
Table 1 Neurological diseases and conditions associated with
fatigue
Neurological diseases and disorders associated with fatigue
Cerebral vasculitis and cerebrovascular diseases
Channelopathies
Charcot-Marie-Tooth disease type 1 (CMT type 1)
Chronic inflammatory demyelinating polyneuropathy (CIDP)
Developmental disorders (cerebral palsy, Arnold-Chiari
malformations)
Dysautonomic states
Encephalitis
Facioscapulohumural dystrophy (FSHD)
Granulomatous disorders (neurosarcoidosis, Wegener’s
granulomatosis)
Hypothalamic and pituitary diseases
Intracranial infections (meningitis and encephalitis)
Metabolic encephalopathy and mitochondrial diseases
Migraine
Motor neuron disease
Multiple sclerosis
Multiple system atrophy
Myotonic dystrophy
Narcolepsy and related sleep disorders
Paraneoplastic (limbic encephalitis, opsoclonus-myoclonus)
Parkinson’s disease and other parkinsonian disorders
Pompe disease and other metabolic myopathies
Cerebral commotion
Guillain-Barre´ syndrome (GBS)
Post-infection fatigue states (poliomyelitis, Lyme disease, Q-fever,
and viral infections)
Postoperative (posterior fossa) surgery
Adapted from Ref. [14]
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In systemic diseases loss of voluntary force-producing
capacity is caused by multisystemic consequences of the
underlying disease. In neurological disease a distinction
can be made between fatigue caused by disease at the level
of the CNS (central fatigue) versus fatigue caused by dis-
ease at the level of the PNS (peripheral fatigue).
Neurological diseases can be located at various levels of
the nervous system, such as the motor cortex, the spinal
cord, the peripheral nerve, the neuromuscular junction or
the muscle itself [107]. Most of these structures are either
important feedback pathways for the perceived effort or
important in voluntary force-producing capacity of the
muscle. Presumably for that reason, severe fatigue is
commonly seen in a variety of neurological diseases.
Central fatigue
Central fatigue is the term generally used when symptoms
result from either psychiatric disease or pathology in the
CNS. This can result in either difficulty with sustaining
physical activities and/or impaired cognitive functioning.
For example, patients with structural lesions in brain areas
important for cognitive processing will have limited ability
to sustain concentration and endure mental tasks (mental
fatigue) [5, 11, 13, 14]. Psychiatric diseases may disturb
neuronal processing in the CNS, for example, in depression
there is reduced internal input from the CNS, which results
in loss of interest and motivation and an exaggerated sense
of fatigue [14]. Loss of voluntary force-producing capacity
of the muscles during exercise due to central mechanisms
seems to result from suboptimal input from the CNS. This
is observed in patients with diseases disrupting the motor
cortex or the motor pathways of the CNS such as multiple
sclerosis [84]. Endocrine disturbances as seen in hypotha-
lamic-pituitary diseases may give rise to profound chronic
fatigue [14]. Temporal hypothalamic-pituitary dysregula-
tion is also responsible for fatigue as seen in the over-
trained athlete syndrome [3].
Peripheral fatigue
Peripheral fatigue, which is similar to muscle fatigability, is
likely to occur in a patient showing a topographic pattern of
muscle weakness or sensory disturbances at neurological
examination based on dysfunction of the lower motor unit
or sensory nerves. Patients with metabolic myopathies (e.g.,
Pompe disease), with disorders at the level of neuromus-
cular transmission (e.g., myasthenia gravis), with disorders
affecting the peripheral nerves [e.g., GBS and Charcot
Marie Tooth type 1 (CMT type 1)] and the anterior horn
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Fig. 1 Fatigue as a multidimensional concept implemented in the
World Health Organization’s Classification of Functioning, Disabil-
ity, and Health. The multidimensional concept of fatigue is integrated
in the World Health Organization’s International Classification of
Functioning, Disability and Health (WHO-ICF), representing the
effect of disease on body function and structure, activity and
participation of the patient [1]. Both experienced fatigue and
physiological fatigue have an effect on activity and participation
and are in most diseases related to health status and disease severity.
Psychosocial factors have an influence on fatigue and on activity and
participation. The numbers indicate at which level the different
treatment strategies have an effect on fatigue: I treatment of
underlying disease; II rehabilitation and exercise; III pharmacothe-
rapeutics; IV cognitive behavior therapy
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cells (e.g., motor neuron disease) can all suffer from
peripheral muscle fatigability, which is characterized by
failure to sustain the force of muscle contraction over time.
In patients with myopathies, muscle fatigability is enhanced
due to structural changes or altered muscle metabolism in
the muscle, which hampers muscle contraction. When
motor conduction is impaired, this leads to decreased
recruitment of motor units, resulting in an earlier occur-
rence of muscle fatigability [14]. Myasthenia gravis is
characterized by rapid progressive reduction of muscle
strength with repeated muscle contraction with (partial)
recovery after a period of rest. This phenomenon of inability
to sustain physical activities is caused by anti-acetylcholine
(Ach) receptor antibodies and a reduction in the number of
ACh receptors of the neuromuscular junction [19].
Fatigue of central origin in neuromuscular disease
Interesting is the finding that patients with PNS disease
also suffer from a generalized form of fatigue, which
originates at the level of the CNS. This should not be
confused with muscle weakness or (exercise induced)
muscle fatigability. Previously, it was thought that gen-
eralized fatigue was caused by skeletal muscle hypoxia or
anaerobiosis; however, these metabolic changes should
lead to muscle rigor [69, 73]. Furthermore, one would
expect that the primary motor cortex tries to compensate
for the decrease of generated force by recruiting the max-
imum number of motor units; however, this is not seen
during maximal exercise [87]. For example, in muscle
disease, if muscle metabolism is beforehand affected, this
will result in a continuous afferent feedback to the CNS.
The CNS will minimize activities to protect further damage
to the muscles (central governor model). In case of muscle
weakness an increase in applied effort is needed to perform
the same activities as a healthy person. This will lead to a
higher perceived exertion at the level of the primary
somatic sensory cortex and an earlier occurrence of fatigue
[14, 69]. In neuro-inflammatory diseases, e.g., post-polio-
myelitis syndrome or chronic inflammatory demyelinating
polyneuropathy (CIDP), fatigue may arise from dysregu-
lation of the neuro-endocrine system. The local
inflammatory process in the muscle or nerves may trigger a
systemic inflammatory response, which causes neuro-
endocrine dysregulation.
Experienced fatigue
Experienced fatigue is the patient’s perception of his or her
level of fatigue in daily life, which is alike to feeling or
sense of fatigue [14, 107]. This reflects to what extent
individual patients notice the increase in effort needed to
complete daily activities and their limitations in endurance
during sustained physical and mental activities [107]. It is a
subjective form of fatigue. The way how fatigue is exper-
ienced is influenced by psycho-sociological factors of the
patient, such as attributions towards fatigue, coping
mechanisms, overall well-being and social circumstances
(Fig. 1) [101]. For example, patients who are stress-sensi-
tive or encounter a stressful event in life are often in a fight
or flight state, characterized by activation of the sympa-
thetic nervous system and initiation of the acute stress
response via the hypothalamic–pituitary–adrenal axis.
These prolonged stress responses may result in exhaustion
and feelings of fatigue. Certain individual patient charac-
teristics, such as emotional state and lack of motivation,
may cause a dissociation between the level of internal input
(motivational and limbic) and that of the perceived signal
of performed effort [14]. This dissociation is responsible
for an increased perception of fatigue. Experienced fatigue
and physiological fatigue can be related to each other, but
do not necessarily co-occur within individuals. In CMT
type 1, facioscapulohumeral dystrophy (FSHD) and myo-
tonic dystrophy, central fatigue (not peripheral fatigue)
correlates with experienced fatigue; however, in GBS no
correlation has been found between either peripheral or
central fatigue [35, 81].
How to assess fatigue
The broad range of mechanisms underlying fatigue, its
multi-dimensional character, confounding factors and dif-
ferent manifestations of fatigue put high demands on the
way fatigue is measured. It is often difficult to assess the
difference in severity of fatigue among individuals. Ne-
vertheless, quantification of fatigue and its impact on the
patient’s life are important for good insight in the overall
condition of the patient and may be helpful in deciding
which supportive measures should be taken to alleviate
fatigue [72].
Several methods have been developed to assess the level
of fatigue. These measurements can be divided into two
categories. The first one, generally based on patient-
reported outcome measures, focuses on experienced fati-
gue. The second category is based on objective tests and
outcomes, and focuses on physiological fatigue [22, 58].
The different techniques quantifying the severity of each
form of fatigue will be discussed in the next paragraphs.
Ways to measure experienced fatigue
Experienced fatigue needs to be quantified via patient-
reported outcome measures (questionnaires). Most of these
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questionnaires are designed for use in daily practice, can be
completed in a limited amount of time and provide the
physician with an estimate of the severity of fatigue and its
impact on the patients’ daily life. To measure treatment
effects or fluctuations in severity of the underlying disease,
a scale should be responsive to changes over time [22]. A
distinction is made between unidimensional and multidi-
mensional scales. A unidimensional scale approaches
fatigue as a single construct, while multidimensional scales
assess several aspects of fatigue, such as physical, cogni-
tive and psychosocial aspects. An elaborate review by
Dittner et al. [22] gives a systematic overview of 10 uni-
dimensional and 20 multidimensional scales for the
measurement of fatigue. It also provides guidance on
choosing the appropriate scale for a particular patient
population.
An example of a unidimensional fatigue scale frequently
used in neuromuscular disorders is the Fatigue Severity
Scale (FSS). This test is easy to use in clinical practice, as
the nine items of the test can be answered within less than 5
min. The FSS measures fatigue by assessing the conse-
quences of fatigue on daily functioning. The scores of the
scale can range from 1 (no fatigue) to 7 (extremely fati-
gued). An average score of 4 and higher is indicative for
fatigue, and a score of 5 and higher for severe fatigue [27,
40, 45, 56, 64]. The FSS demonstrated good internal con-
sistency (Cronbach’s alpha coefficient = 0.88), test–retest
reliability (Cohen’s kappa value = 0.84) and discrimina-
tive validity in studies among patients with immune-
mediated polyneuropathies, multiple sclerosis and Pompe
disease [22, 38, 40, 56].
An example of a multidimensional fatigue scale is the
Checklist Individual Strength (CIS). This is a 20-item
questionnaire that evaluates fatigue severity in general (i.e.,
not related to specific daily activities), concentration,
motivation and the level of physical activity [81]. The CIS
was not specifically validated for patients with neuromus-
cular disorders, but has shown good psychometric
properties in other populations (internal consistency;
Cronbach’s alpha coefficient = 0.90) and discriminative
validity between multiple sclerosis and healthy controls)
[7, 89, 97]. The CIS has been used to assess fatigue in
patients with chronic fatigue syndrome, multiple sclerosis,
FSHD, CMT type 1 and myotonic dystrophy [81, 83, 89,
97, 101].
Ways to measure physiological fatigue
There is limited experience with methods that have the
potential to objectively quantify the level of physiological
fatigue. The following methods can be used: electrophys-
iological measurement of decline in muscle force after
exercise (peripheral fatigue); electrophysiological meas-
urement of central activation failure (central fatigue)
[107] and; neuropsychological assessment (central fatigue)
[14].
The most direct method for measuring peripheral fatigue
is measuring the generated force by electrical stimulation
during rest and after muscle contraction and to look at the
decline in generated force (Fig. 2). The decline in force
reflects the severity of fatigue. It also shows the change in
muscle contractibility, such as a fatigue-induced delay of
the muscle relaxation phase (Fig. 2) [18]. During the
contraction a decline over time of the maximal voluntary
force can be observed (muscle fatigability). The actual
force exerted is usually expressed as a percentage of the
maximal force (e.g., 70% of the maximal voluntary con-
traction). With a surface electromyogram a decline in fiber
conduction velocity may be indicative for peripheral fati-
gue [107].
When central fatigue is present, suboptimal input from
the CNS to activate the muscle results in a decrease in
maximal force generating capacity of the muscle. This is
defined as central activation failure (CAF). When during
maximal voluntary contraction the generated force
increases with electrical stimulation, this is indicative for
CAF (Fig. 2). When CAF increases during exercise, this is
supportive for the presence of central fatigue. CAF can be
confirmed with a twitch-interpolation technique, magnetic
and electrical stimulation of the motor cortex and readiness
potential. For a commentary on these methods, the review
by Zwarts et al. is recommended [107].
A method to evaluate mental fatigue is through neuro-
psychological assessment. Via this assessment cognitive
Fig. 2 Schematic representation of physiological fatigue. The figure
shows the decline over time of the maximal voluntary force (on the
Y-axis). The ‘at-rest twitches’ are visible before and after the
contraction, with the post-contraction twitch being clearly lower and
slower, indicative of peripheral fatigue. The arrows indicate the
moments of superimposed electrical endplate stimulation. The twitch
interpolation has induced small increments in muscle force with
examples of a negligible and a large central activation failure (CAF).
A (near) absent response indicates a full voluntary activation of the
muscle. This figure originates from Ref. [107]
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domains of memory, learning, attention and information
processing are evaluated. Patients with mental fatigue
perform worse on these tests, and their performance will
decline during the assessment session [5, 11].
Fatigue in neuromuscular disorders
Neuromuscular disorders include a wide range of disease
entities causing abnormalities in muscle function and/or
sensory function. These may be caused by dysfunction at
the level of the muscle itself, the neuromuscular junction,
the peripheral nerve or at the level of the anterior horn cell
in the spinal cord or brain stem. Typical features of neu-
romuscular disorders comprise muscular atrophy, muscle
weakness and sensory disturbances such as pain, tingling-
feelings, hyperpathy or hypoesthesia [19].
Fatigue has been an under-recognized aspect of neuro-
muscular disorders over a long period of time. As we have
mentioned before, fatigue on one hand is caused by a local
effect on muscle function (peripheral fatigue), and on the
other hand fatigue originates at the level of the CNS
because of feedback about the pathological state of the
PNS. This fatigue protects the muscles from further dam-
age by down-regulating physical activities. This is
illustrated by the fact that fatigue of central origin was
recorded in 36–41% of patients with a neuromuscular
disorder (FSHD, CMT type 1 and myotonic dystrophy) vs.
12% in controls [82]. These high percentages, however,
were not found in a small study in GBS patients [35]. In
patients with FSHD, CMT type 1 and myotonic dystrophy,
fatigue of central origin correlated positively with the level
of experienced fatigue. In GBS patients, this correlation
has not been found [35, 81]. It should be noted that most
individuals with severe fatigue, but without demonstrable
muscle weakness and/or elevated serum creatine kinase
(CK) levels do not have a neuromuscular disorder. Thus,
fatigue as the only complaint excludes in most cases the
presence of a neuromuscular disorder [59]. An exception to
this rule are mitochondrial myopathies or other metabolic
disorders in which clear exercise intolerance can reported
by patients where muscle weakness is not always present at
the time of the neurological examination [14]. Further-
more, fatigue can persist as a residual symptom after a
neurological illness, of which GBS and CIDP are good
examples [38, 64].
Other disorders in which increased levels of fatigue have
been reported are myasthenia gravis, post-poliomyelitis
syndrome, immune-mediated neuropathies, FSHD, CMT
type I, myotonic dystrophy and Pompe disease [38, 40, 43,
48, 53, 64, 71, 78, 81]. The prevalence of fatigue in various
neuromuscular disorders reported in the literature ranges
from 38 to 86% (Table 2). The reported prevalence of
fatigue in neuromuscular disorders compares with the
prevalences of fatigue in multiple sclerosis (range from 53
to 92%) [10], where fatigue is recognized as an important
symptom [54]. To be aware of the impact of fatigue in
neuromuscular disease, it is valuable to compare its high
prevalence with the low prevalence of severe fatigue in
healthy individuals (range 5–18% and mean FSS 2.3–3.3)
[64, 78, 92]. The ranges seen in the mentioned prevalences
are explained by differences in study population, used,
assessment method and used definition of severe fatigue
(e.g., cutoff point).
In the following section of this review we will discuss two
different neuromuscular disorders for which fatigue has
been reported as an important feature. GBS will be taken as
an example of immune-mediated polyneuropathies and;
Pompe disease as an example of metabolic myopathies.
Fatigue after Guillain–Barre´ syndrome (GBS)
GBS is an acute post-infectious immune-mediated
polyneuropathy, characterized by rapidly progressive,
symmetrical limb weakness and areflexia. Sensory distur-
bances, autonomic dysfunction and respiratory insufficiency
often occur during its disease course. The severity of
Table 2 Prevalences of severe
fatigue in neuromuscular
disorders
CIS checklist individual
strength, FIS fatigue impact
scale, FSS fatigue severity scale,
MFI multidimensional fatigue
inventory, VAS-F visual
analogue scale for fatigue, NA
not applicable
Neuromuscular disorder Prevalence
of severe
fatigue (%)
Fatigue scale
used to assess
severity of fatigue
Guillain-Barre´ syndrome [28, 38, 64, 78] 38–86 FSS, FIS, VAS-F
Pompe disease [40] 67 FSS
Myasthenia gravis [71] 82 FIS, MFI
Post-poliomyelitis syndrome [53] 80 NA
Facioscapulohumural dystrophy [48, 81] 51–61 CIS
Myotonic dystrophy [48, 81] 53–74 CIS
Charcot-Marie-Tooth disease type 1 (CMT type 1) [48, 81] 55–64 CIS
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neurological deficits differs among patients and usually
reaches a plateau phase within 2 weeks, which is indicative
of the start of the recovery phase. Final outcome varies
greatly among patients and ranges from severe residual
weakness to complete recovery [4, 99]. CIDP may be con-
sidered a chronic variety of GBS [98].
Patients experience fatigue already at the onset of GBS,
and it can surprisingly persist for many years, even after
total recovery of muscle weakness [38]. Fatigue in GBS
was sporadically reported in the literature until 1999, when
a cross-sectional case control study showed that fatigue is
an essential and incapacitating residual symptom in
patients with immune-mediated polyneuropathies [64].
Eighty percent of patients that recovered from GBS or
CIDP or had ongoing CIDP suffered from severe fatigue.
The patients stated that being severely fatigued leads to
tremendous impairment in their daily life and social
activities. As a consequence their quality of life was
reported to be negatively affected in the long term. Some
confounding factors could have affected the outcome of the
study addressing fatigue in GBS. Sleep disorders, depres-
sion and level of physical activity were not systematically
evaluated in the study. However, other studies confirmed
the high prevalence of fatigue in GBS, being 38% [78],
40% [28] and 86% [64]. Part of the differences in estimated
prevalence can probably be explained by differences in age
between study populations, as severe fatigue showed a
positive correlation with age in GBS [38]. Severe fatigue
does not seem to be related to clinical variables, antecedent
infections or the severity of the neurological dysfunction in
the initial phase of GBS [38, 64], except that severe fatigue
has a higher prevalence in female GBS patients (74% in
females versus 45% in males, p = 0.003). This difference
in sex ratio is also seen in patients with chronic fatigue
syndrome and can probably best be explained by endocrine
differences between males and females [77]. A conven-
tional nerve conduction study failed to show a relation
between experienced fatigue and the occurrence of physi-
ological fatigue/residual nerve dysfunction [37]. However,
it could well be that newer or more advanced electro-
physiological methods could be helpful to study this
relationship. It has been added that CMAP scans poten-
tially could be helpful to study this relationship [24].
Another interesting finding was that severely fatigued
GBS and CIDP patients showed a normal activity level,
which was independent of their neurological condition. We
presume that this neglect of patients’ impaired load
capacity may even increase symptoms of fatigue, as the
actual performance of the patient does not match the
patient’s physical load capacity [12]. GBS not only affects
the peripheral nerves, but also has an impact on psycho-
social status. This may lead to a disturbed interplay
between the structural and/or functional integrity of
sensory, motor and cognitive symptoms, which may
increase the sense of fatigue.
In general, the occurrence of fatigue in GBS seems
independent of the severity of (residual) neurological def-
icits [37, 38, 64]. This differs from findings in other
neuromuscular disorders, where severely affected patients
experience higher levels of fatigue [40, 49]. The fact that
GBS is an acute and monophasic disease may explain at
least part of the differences found, as the other mentioned
neuromuscular disorders are often chronic diseases and
progressive in nature. In GBS and in CIDP it could well be
that dysregulation of the hypothalamic–pituitary–adrenal
axis accounts for residual fatigue, which could be linked
to the antecedent infections seen in GBS and smoldering
low-grade infections possibly going on in CIDP, because
similar immune-mediated fatigue is seen as a residual
symptom after an infectious illness [46]. Dysautonomia
could also be an important contributor to fatigue [14] and is
frequently seen in patients with GBS. At the moment fur-
ther prospective studies in GBS are being executed (as part
of the Dutch ‘Graph study’) to investigate the relation
between fatigue in relation to dysautonomia, preceding
infections, severity of disease and the occurrence of pain
(L. Ruts, personal communication). In conclusion, we
could state that peripheral fatigue is a more important
contributor in the initial phase of the GBS. However,
because feelings of fatigue persist after resolution of neu-
rological symptoms, other factors must be responsible for
fatigue in the long run. Post-infectious fatigue, dysauto-
nomia and psycho-sociological consequences of the disease
may be these causative factors.
Fatigue in Pompe disease
Pompe disease (glycogen storage disease type II, acid
maltase deficiency) is an autosomal recessive disorder
caused by deficiency of lysosomal acid alpha-glucosidase.
As a result, glycogen accumulates in lysosomes of several
body tissues [52]. The disease presents as a spectrum of
phenotypes. Patients with the classic infantile form are at
the severe end of the spectrum. They suffer from a rapidly
progressive disease course. Presentation is shortly after
birth with hypotonia, feeding difficulties or respiratory
problems. A hypertrophic cardiomyopathy is characteris-
tically present. Patients usually die before the first year of
life because of cardiorespiratory failure [94]. On the other
end of the spectrum are children and adults with Pompe
disease in which skeletal muscles are primarily affected. In
these patients the disease is slowly progressive. The
proximal, paraspinal and respiratory muscles are most
involved. Patients may eventually become wheelchair
bound and dependent on (nocturnal) ventilation [42, 43].
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Fatigue is a frequently experienced symptom in adults
with Pompe disease and may have a disabling impact on
the lives of patients [40]. Until recently, fatigue in Pompe
disease did not receive much attention and was not struc-
turally assessed. Incidentally fatigue had been reported in
case reports and small patient populations of up to 16
subjects [20, 62, 65, 85, 105]. In a study on the natural
course of Pompe disease in 54 patients, fatigue was rather
unexpectedly reported to be the presenting symptom in
25% of the patients [43]. Seventy-six percent of the study
population indicated that fatigue had an important impact
on their daily life. Subsequently, fatigue was studied by
using the FSS in more detail in an international group of
225 patients [40]. It was demonstrated that fatigue occurs
in the majority (78%) of Pompe patients (FSS score C4)
and severe fatigue (FSS score C5) in two-third of the
patients [40]. The mean FSS scores differed significantly
from healthy controls (mean FSS score of 5.2 versus 2.9,
p \ 0.001). Patients who did not use a wheelchair and
respiratory support were significantly less fatigued when
compared with patients using either or both (p = 0.01)
[40]. It is of interest that Pompe patients reported only
slightly lower levels of cognitive well-being in comparison
with the general population [41]. This indicates that
depression probably does not contribute to the observed
prevalence of experienced fatigue, in contrast to, for
example, multiple sclerosis, for which depression was
found to have a substantial influence on the severity of
fatigue [74].
In Pompe disease the accumulation of glycogen in
muscle fibres leads to structural changes of the muscle,
which impairs muscle contraction, and in a more advanced
state even destructs muscle fibers. This results in muscle
weakness, muscle atrophy and muscle fatigability
(peripheral fatigue). When patients are performing physical
activities, they experience burning sensations of the prox-
imal muscles and a heavy-legged feeling, which limits their
force-producing capacity. In Pompe disease and other
metabolic myopathies, such as McArdle’s disease, muscle
metabolism is altered, and certain metabolites could impair
skeletal muscle contraction through a direct action. This
would be perceived as an increase in effort by the CNS,
which then responds with down-regulating of activities to
preserve homeostasis in the muscle [69].
Respiratory dysfunction, due to diaphragmatic weakness
and weakness of the respiratory muscles, is often present in
Pompe patients and can also account for an increase in
fatigue of central origin. Patients have to increase their
respiratory effort to sustain adequate ventilation during
exercise, or even already at rest. By feedback from the
respiratory system (hypercapnia and hypoxia), fatigue is
perceived at the CNS, and adequate ventilation is restored
by decreasing the performed physical effort [14, 69].
Second, nocturnal hypoventilation leads to a decreased
oxygenation of the brain and respiratory acidosis. Due to
altered respiratory function the normal sleep pattern is
disrupted [63]; as a consequence patients are not well
rested, feel fatigued and suffer from day-time sleepiness
during the day.
The pathophysiology of fatigue in Pompe disease still
remains to be established, as this topic has not yet been
investigated. Muscle fatigability of the proximal muscles
plays an important role in Pompe patients, as they have
difficulties in sustaining physical activities. Besides this
localized form of fatigue, the occurrence of generalized
fatigue is explained by the central governor model [14, 69].
Respiratory dysfunction also contributes to the level of
fatigue perceived at the CNS.
Implications for treatment
Fatigue is a complex and multifaceted entity. In order to
determine the treatment strategy for an individual patient, it
is important to define the type of fatigue and the underlying
factors that contribute. First, the implications of fatigue for
the patient need to be investigated. This can be done by
assessing the level of fatigue and its impact on daily
activities and general well being. Second, potential
behavioral and psycho-sociological factors need to be
identified that contribute to the experienced level of fati-
gue. Currently one or more of the following optional
treatment strategies for fatigue in neuromuscular disorders
can be used: (1) (symptomatic) treatment of the underlying
disease, (2) rehabilitation and exercise, (3) pharmacother-
apeutics directed to treat fatigue and (4) cognitive therapy.
Figure 1 shows how the different treatment strategies act
on fatigue and the different domains of the WHO-ICF
model.
Treatment of underlying disease and symptoms
When a patient complains of symptoms of fatigue, a
diagnostic workup should be done to identify potential
causes of fatigue. As mentioned, fatigue can be a symptom
of various (neurological) diseases, but also other underly-
ing diseases may cause fatigue [14]. When the patient has
already been diagnosed with a disorder that may explain
fatigue, other causes like co-morbidity need to be ruled out.
When possible, start or optimize treatment of the under-
lying disease, and eliminate other causal factors that may
contribute to fatigue. For example, treatment of myasthenia
gravis patients with adequate dosages of pyridostigmine
can improve the clinical well-being and reduce feelings of
fatigue [39, 47]. In a pilot study of late-onset Pompe
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patients treated with enzyme replacement therapy, the
patients experienced a reduction in fatigue over a period of
8 years of treatment [93]. The experienced increase in
energy level made them more independent in daily life and
improved their participation in social activities.
Furthermore, in patients with neuromuscular disorders it
is of utmost importance to rule out sleep-disordered
breathing as a cause of sleepiness and fatigue during the
day [76]. Nocturnal hypoventilation is frequently seen in
neuromuscular patients with diaphragmatic weakness or in
patients with obstructive apnoea or hypopnea. Besides
hypoventilation, obstructive sleep apnea causes a disrupted
sleep pattern, which results in a lowered quality of sleep
[86]. Symptoms explained by nocturnal hypoventilation
often herald complete respiratory failure by months or even
years. Diaphragmatic weakness is often seen in Pompe
disease and is present when there is a significant decline in
pulmonary function when pulmonary function is measured
in the sitting and the supine position [96]. A decline of 25%
or more is called postural drop. Sleep-disordered breathing
can be measured with sleep studies. When mechanical
ventilation is implemented in patients suffering from noc-
turnal hypoventilation or sleep disordered breathing,
symptoms of fatigue can be tremendously reduced [76].
Rehabilitation and exercise
A well-fitted rehabilitation program can help patients to use
their energy more efficiently. For example, implementation
of ergo-therapeutic devices aimed at improving the ease of
performing daily activities may increase the level of energy
and thereby lessen symptoms of fatigue. Also training in
developing coping strategies aimed at balancing mental and
physical activities and rest may improve the patient’s well-
being. The potential effect of exercise programs on the level
of fatigue was investigated in several studies [12, 25, 34,
79]. In patients recovered from GBS and in patients with
ongoing but well-treated CIDP who suffer from severe
fatigue, implementation of tailor-made exercise programs
resulted in a reduction of 20% of self-reported fatigue. This
improvement had been maintained at 2-year follow-up [33,
34]. These findings are consistent with results reported for
healthy sedentary individuals (15%) and patients with
multiple sclerosis (22%) after completion of an exercise
program [75, 80]. However, the decrease in experienced
fatigue in GBS after exercise therapy could not be explained
by an increase in physical fitness [12]. Hypothetically, it
could be that training also has a beneficial effect on the
neuro-endocrine system and levels of neurotransmitters,
which may reduce perception of fatigue. Additionally,
recognition of the patients’ complaints of fatigue and the
beneficial effect of support from fellow patients within the
training group are also potential factors that can reduce
experienced fatigue [12, 34]. Figure 3a, b visualizes the
relationships among training, physical fitness, activity and
psychosocial factors in a model. Figure 3a shows the rela-
tionships as was hypothesized before the start of the training
study and Figure 3b the remodeling after analysis of the
results of the study [12, 34].
Although strong evidence for a beneficial effect of
exercise on experienced fatigue in neuromuscular disorder
presently is relatively scarce, a low-intensity training
schedule is likely to have a positive effect on fatigue and
the general condition of patients with a neuromuscular
disorder. Regular activity prevents physical deconditioning
and muscle wasting. This was also shown in a rat model for
post-poliomyelitis where physical activity reduced the size
of the chronically enlarged motor units in denervated
muscles [91].
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Fig. 3 Model of fatigue in
immune-mediated
polyneuropathies. a Represents
the hypothetical model of the
mechanisms between the
different domains in relation to
physical training. b Is the model
resulting from the correlations
between the change scores of
the different domains as a result
of the training intervention.
Thickness of lines between
domains represents the strength
of the relationship. Figures
adapted from Ref. [12]
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Pharmacotherapeutics
The efficacy of pharmacotherapeutic drugs such as aman-
tadine, modafinil, albuterol and aminopyridine has not yet
been convincingly proven for the treatment of fatigue in
patients with neuromuscular disorders. Amantadine was
shown to be effective in one-third to half of all treated
multiple sclerosis patients [15, 55, 67]. Amantadine,
however, did not show a beneficial effect in a well-powered
randomized controlled trial on residual fatigue in patients
who were in a good clinical condition after recovery from
GBS [36]. In FSHD the effects of albuterol had no effect on
experienced fatigue [95]. Modafinil has shown some ben-
eficial effect in myotonic dystrophy; however, these were
studies with small populations and a relatively short fol-
low-up [17, 61, 90, 103]. Clinical trials studying the
efficacy of pharmacotherapeutics as treatment for fatigue in
other neuromuscular disorders are still lacking.
Cognitive behavior therapy
Patients’ attitudes towards fatigue, coping mechanisms and
psychosocial circumstances attribute to the level of expe-
rienced fatigue [101]. Patients may experience stress,
depression and anxiety caused by disease-related social
consequences, such as loss of employment, failure to fulfill
family responsibilities and limitations in their social life. If
necessary, patients can be supported with occupational
rehabilitation. Cognitive behavioral therapy and psycho-
logical support have been shown to have a positive effect
on experienced fatigue in cancer patients [68]. Whether the
same results can be obtained in patients with neuromus-
cular disorders needs further investigation.
Conclusion and future lines of investigation
The impact of fatigue on the lives of patients suffering
from neuromuscular disorders has remained long unnoticed
and has only recently been recognized as an important
subject to be addressed in both clinical practice and
research [6, 14, 38, 40, 64, 104, 107]. A high prevalence of
fatigue was found in Pompe disease, GBS, post-poliomy-
elitis, hereditary polyneuropathy, myasthenia gravis and
myotonic dystrophy [38, 40, 48, 53, 64, 70]. The preva-
lence of severe fatigue in these disorders was estimated to
be similar to that in patients with multiple sclerosis [50].
Fatigue can be subdivided into experienced fatigue and
physiological fatigue. The severity of both experienced
fatigue and physiological fatigue is influenced by psycho-
sociological factors. In most neuromuscular disorders, but
not in GBS as far as we know now, it also depends on
disease severity [38, 40, 49, 64, 100]. The pathophysiologic
mechanisms causing fatigue in neuromuscular disorders are
not completely understood. Most likely there are two main
pathways that lead to physiological fatigue: first, the
pathology located in the PNS causes muscle fatigability by
hampering muscle contraction, disturbance of muscle
metabolism and inability to activate enough motor units
(peripheral fatigue). Because patients with neuromuscular
diseases have to compensate for their loss of function by
increasing their motor input to accomplish the same
activities as a healthy person, the perceived level of effort
at the CNS is higher, and patients become more easily
fatigued. Additionally, the disease state of the muscles is
continuously sensed at the level of the CNS, which will
result in a constant feeling of fatigue of central origin,
because body homeostasis needs to be maintained. Besides
this flexible interactive feedback and feed forward system
as described in the central governor model, other causes of
central fatigue are proposed in patients with neuromuscular
disorders [81]. Pathology of the PNS can eventually induce
functional changes in the motor cortex, which may be a
consequence of deconditioning and/or the relatively large
demands put on the affected neuromuscular system [16, 21,
60]. This indirectly results in central fatigue due to CAF.
Second, there is some evidence that pathology in neuro-
muscular disorders is not always restricted to the PNS and
can affect the CNS as well. In FSHD and myotonic dys-
trophy, this was revealed using magnetic resonance
imaging and somatosensory-evoked potentials [26, 66].
Although central fatigue usually correlates positively with
the level of experienced fatigue, this correlation was not
clearly found in ‘neurologically well-recovered’ GBS
patients [35, 81].
The differences of several aspects of fatigue found in
GBS, as compared to other neuromuscular disorders, may
lie in the fact that GBS is an acute and monophasic disease,
often preceded by an infection. In contrast, the others
neuromuscular diseases are often chronic and mostly pro-
gressive diseases.
For the management of fatigue in neuromuscular
disorders, it is advised to start with optimizing treatment
of the underlying disease and of possible co-existing
causes of fatigue. When symptoms of fatigue persist, non-
pharmacological interventions are preferable to pharma-
cotherapeutics, as pharmacotherapeutics have not yet been
proven to be effective for the treatment of fatigue in neu-
romuscular disorders [36]. Further elucidation of the
pathophysiology of fatigue, with special interest in the
central governor model, may help to guide the develop-
ment and proper targeting of new and hopefully effective
pharmacotherapeutics. Meanwhile, the benefit of non-
pharmacological treatments, such as low-intensity physical
training, rehabilitation and cognitive behavioral therapy, as
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treatment options for fatigue in neuromuscular disorders
needs further evaluation. The increasing awareness of
fatigue as an important part of the burden of disease in
neuromuscular disorders is not only important for the
development of new treatment strategies, but also for
improvement of current patient care.
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